Shots:

• The EMA’s CHMP has adopted the positive opinion recommending conditional marketing authorization for the V920 Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP- live)- indicated for active immunization of individuals ≥18yrs. to protect against EVD caused by Zaire Ebola virus
• If EC affirmed CHMP opinion- it will grant centralized marketing authorization with unified labeling to the V920 Ebola Zaire Vaccine and will be authorized under the name Ervebo
• V920 is a recombinant- replication-competent Ebola vaccine- consisting of a vesicular stomatitis virus to provoke a neutralizing immune response to the Ebola virus. The US FDA has accepted its BLA in Sept’2019 and granted it PR with a PDUFA date as Mar 14- 2020

Click here to­ read full press release/ article 

Ref: Merck | Image: Merck